Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Executive Summary
Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.
You may also be interested in...
Will A Dividend Keep Investors Happy As Amgen Waits For Its Pipeline To Pan Out?
Amgen outlines its strategic priorities through 2016, but analysts and investors seem more concerned with near-term initiatives that could pan out before year's end.
Amgen At A Crossroads: Analysts Question Capital Allocation, M&A,D-mab
Amgen Inc. is going through a transformational time as many of its top-selling drugs are maturing and its latest potential blockbuster franchise tries to find a foothold in the market. While Prolia/Xgeva (denosumab) offers a lucrative lifeline for the big biotech, investors are getting anxious about the company’s future; pushing for a dividend and for clarity about its strategy.
Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?
Valeant Pharmaceutical International Inc.'s hostile bid for Cephalon Inc. has all the earmarks of a pharma battle of our times: it pits an R&D-adverse, opportunistic company against a specialty pharma company that is increasingly betting on mid-to-long term innovation.